Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
08:05pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
Data to be Available in Fourth Quarter 2022 Data to be Available in Fourth Quarter 2022
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
01:51pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
11:17am, Thursday, 31'st Mar 2022
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
08:05pm, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
MENLO PARK, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat s
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
Corcept (CORT) Up 5.8% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bragar Eagel & Squire, P.C. Is Investigating Corcept, Medallion, Clariant, and Anavex and Encourages Investors to Contact the Firm
02:00am, Thursday, 10'th Mar 2022 GlobeNewswire
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT), Medallion Financial Corp. (NASDAQ: MFIN), Clariant AG (OTCMKTS: CLZNY), and Anavex Life Sciences Corp. (NASDAQ: AXVL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
CORT Sees Increase in Sales, Customer Confidence With Vertebrae 3D Technology
03:00pm, Tuesday, 08'th Mar 2022 Kwhen FinanceCushings Syndrome Market to See Incredible Growth By 2022-2028 | Corcept Therapeutics Inc., HRA Pharma, Strongbridge Biopharma plc., and Novartis AG
09:23am, Monday, 28'th Feb 2022 OpenPR
The Cushings Syndrome market report presents the global Cushings Syndrome sales and revenue by companies, regions, type and application and forecast to 2028. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market
Corcept Therapeutics (CORT) Investor Presentation - Slideshow
06:44pm, Thursday, 24'th Feb 2022 Seeking Alpha
3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin
11:58am, Wednesday, 23'rd Feb 2022 The Motley Fool
Making medicines is a more reliable path to share price appreciation than memes.
3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin
11:58am, Wednesday, 23'rd Feb 2022 The Motley Fool
Making medicines is a more reliable path to share price appreciation than memes.
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss
02:54pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.
Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss
11:35am, Wednesday, 16'th Feb 2022
Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.
Corcept Therapeutics (CORT) Q4 2021 Earnings Call Transcript
06:00am, Wednesday, 16'th Feb 2022 The Motley Fool
CORT earnings call for the period ending December 31, 2021.
